摘要
背景:骨肉瘤被认为是最常见的原发性骨恶性肿瘤。肺转移是导致死亡的主要原因,也是预测阴性患者预后的最一致的因素。n骨肉瘤。第三代含氮双膦酸盐,如唑来膦酸,已被证明能减少骨转移引起的骨溶解,并具有高度的选择性定位。并保留在骨中,从而使它们成为治疗骨转移的有吸引力的药物。研究表明,唑来膦酸对骨肉瘤细胞具有多种抗肿瘤作用。在体外,包括抗增殖、抗血管生成和免疫调节作用。唑来膦酸对骨肉瘤Ⅰ期原发肿瘤生长和肺转移的影响存在争议,限制了其临床应用。 目的:综述唑来膦酸对骨肉瘤原发肿瘤负担和肺转移的影响。同时,我们还分析了佐菌素的临床疗效。单用立膦酸联合化疗药物治疗骨肉瘤。 结论:唑来膦酸在体外对骨肉瘤具有不同的抗肿瘤作用,但其体内效应仍存在争议。CLA需要进一步的临床和临床研究。研究唑来膦酸治疗骨肉瘤的疗效。
关键词: 双膦酸盐,骨溶解,骨肉瘤,肺转移,唑来膦酸,骨。
图形摘要
Current Drug Targets
Title:Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma
Volume: 19 Issue: 5
关键词: 双膦酸盐,骨溶解,骨肉瘤,肺转移,唑来膦酸,骨。
摘要: Background: Osteosarcoma is considered the most frequent primary bone malignancy. Lung metastasis is the leading cause of death and the most consistent factor for predicting negative patient outcome in osteosarcoma. Third-generation nitrogen-containing bisphosphonates, such as zoledronic acid, have been shown to reduce osteolysis induced by bone metastasis and exhibit highly selective localization and retention in bone, thus making them attractive agents in the treatment of bone metastasis. Studies have shown that zoledronic acid exerts pleiotropic anti-tumor effects against osteosarcoma cells in vitro, including anti-proliferative, anti-angiogenic, and immunomodulatory effects. However, the efficacy of zoledronic acid against primary tumor growth and pulmonary metastasis of osteosarcoma is controversial, which has limited its clinical application.
Objective: The present review summarizes the controversial effects of zoledronic acid on primary tumor burden and pulmonary metastases in osteosarcoma. We also analyze the clinical effectiveness of zoledronic acid alone and in combination with chemotherapeutic drugs for the treatment of osteosarcoma.
Conclusion: Zoledronic acid exhibits diverse anti-tumor effects in osteosarcoma in vitro, however, the in vivo effect is still controversial. Further preclinical and clinical studies are needed to clarify the effects of zoledronic acid in osteosarcoma.
Export Options
About this article
Cite this article as:
Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma, Current Drug Targets 2018; 19 (5) . https://dx.doi.org/10.2174/1573399811666150615145409
DOI https://dx.doi.org/10.2174/1573399811666150615145409 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ribozymes in the Age of Molecular Therapeutics
Current Molecular Medicine Dietary Manipulation of Precursor Polyunsaturated Fatty Acids Modulates Eicosanoid and Endocannabinoid Synthesis: A Potential Tool to Control Tumor Development
Current Nutrition & Food Science Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Impact of Cellular Senescence in Aging and Cancer
Current Pharmaceutical Design Mitochondrial Permeability Transition Pore as a Suitable Targ e t for Neuroprotective Agents Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Radiolabelled Peptides: Eon in Radiopharmaceutical
Current Radiopharmaceuticals Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Anti-Cancer Properties of Nigella spp. Essential Oils and their Major Constituents, Thymoquinone and β-Elemene
Current Clinical Pharmacology Targets for Steroid Hormone Mediated Actions of Periodontal Pathogens, Cytokines and Therapeutic Agents Some Implications on Tissue Turnover in the Periodontium
Current Drug Targets p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Vitamin D and miRNAs in Cancer
Current Gene Therapy Structure-Function Relationships of PEDF
Current Molecular Medicine Therapeutics Based on microRNA: A New Approach for Liver Cancer
Current Genomics NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Meet Our Editorial Board Member:
Current Pharmaceutical Design Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design